This is a routine policy initiative involving pharmaceutical pricing negotiations. A-score: Minimal constitutional impact - only marginal capture concern (1/5) as government negotiates drug prices, which could reflect pharma industry influence dynamics but represents normal executive policy function. Policy_change mechanism adds 15% modifier, federal scope adds 20%. Total A-score: 0.16. B-score: Low hype - some media friendliness (3/5) for health policy story, minimal outrage/meme potential. Layer 2 shows minor timing/narrative elements. Total B-score: 4.74. This is standard administrative healthcare policy with no meaningful constitutional implications and minimal distraction value.